CLINICAL TRIALS PROFILE FOR VEKLURY

All Clinical Trials for Veklury

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT04784559 ↗	Trial to Determine the Efficacy/Safety of Plitidepsin vs Control in Patients With Moderate COVID-19 Infection	Recruiting	PharmaMar	Phase 3	2021-06-04	Treatment of patients hospitalised for management of moderate COVID-19 infection
NCT04832880 ↗	Factorial Randomized Trial of Rendesivir and Baricitinib Plus Dexamethasone for COVID-19 (the AMMURAVID Trial)	Not yet recruiting	ASST Fatebenefratelli Sacco	Phase 3	2021-04-06	Background: In the current worldwide medical emergency, a rapid identification of effective therapeutic strategy is crucial. So far, therapy with dexamethasone, remdesivir and baricitinib have been associated with evidence of impact on the clinical impact on COVID-19, but the effect of baricitinib and remdesivir in combination with dexamethasone. The AAMMURAVID trial is endorced and supported by the Italian Regulatory agency (AIFA-Agenzia Italiana del Farmaco)
NCT04853901 ↗	Remdesivir Efficacy In Management Of COVID-19 Patients	Completed	Ain Shams University	Phase 3	2020-07-27	The study is open label randomized interventional phase 3 clinical trial. Patients with confirmed Covid-19 cases who was hospitalized in Two university isolation hospitals (Ain Shams University and Assiut University ) assigned hospitals for isolation.
NCT04871633 ↗	Effectiveness of Remedesvir in COVID-19 Patients Presenting at Mayo Hospital Lahore	Completed	King Edward Medical University	N/A	2020-08-01	Currently, several drugs including Remdesivir, hydroxychloroquine, chloroquine, ritonavir+lopinavir, Tocilizumab, Arbidol and interferon are under randomised controlled trials (RCTs) for efficacy and/or safety evaluations in patients with COVID-19 in different countries. Remdesivir (GS-5734) is among these investigational drugs and some studies reported promising results. Remdesivir is a nucleotide analogue intravenous pro-drug developed by Gilead Sciences, an American biopharmaceutical company, for treatment of Ebola virus during the 2014 Ebola outbreak in Western Africa. Remdesivir shows broad-spectrum antiviral activity against many RNA viruses including SARS-CoV-2 through blocking RNA polymerase thereby terminating RNA transcription. Remdesivir was among the first treatments used in China as the outbreak emerges and it has been reported as potential treatment options for COVID-19 in the USA, China and Italy.
NCT05502081 ↗	Clinical Study to Compare Efficacy and Safety of Casirivimab and Imdevimab Combination, Remdesivir and Favipravir in Hospitalized COVID-19 Patients	Completed	Mansoura University Hospital	Phase 4	2021-11-01	Introduction: Corona Virus induced disease - 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of 2021 year, various advances in pharmacotherapy against COVID-19 have emerged. Regarding antiviral therapy, Casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Standard antiviral therapy against COVID-19 includes Remdesivir and Favipravir. Aim of Study: 1. To compare the efficacy of antibodies cocktail (casirivimab and imdevimab), Remdesivir and Favipravir in reducing 28-day mortality in hospitalized patients with moderate, severe or critical COVID19 2. To compare safety of antibodies cocktail (casirivimab and imdevimab), Remdesivir and Favipravir by monitoring hypersensitivity and infusion related reactions or other significant adverse effects Patients and Population: 265 COVID-19 Polymerase Chain Reaction (PCR) confirmed patients with indication for antiviral therapy is included in this study and will be divided into 3 groups (1:2:2): 1. Group A: REGN3048-3051(Antibodies cocktail (casirivimab and imdevimab)) 2. group B: Remdesivir 3. group C: Favipravir Methods: Study design is single blind non-Randomized Controlled Trial (non-RCT). The drugs of the study are owned by Mansoura University Hospital (MUH), and prescribed by chest diseases lectures of faculty of medicine-Mansoura University. The duration of study is about 6 months after ethical approval.
NCT05911906 ↗	An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.	Not yet recruiting	Peninsula Clinical Trials Unit	Phase 4	2024-06-01	Following an infection with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2), one in ten people will experience persisting symptoms, or develop symptoms which can last for months and even years. These symptoms affect people in different ways and have been demonstrated to broadly impact physical, mental, and cognitive health. This is called Long COVID. Currently, there are no treatments available to address the issues that patients experience but anti-viral medications have been suggested as being potentially effective. This study will recruit patients that have confirmed long COVID and participants will undertake a series of tests to determine their symptoms and the impact that their condition has had on their bodily systems. The total duration of each participant's involvement is approximately 8 weeks, and this will involve 13 visits (15 visits if taking part in Exeter) at the closest study location (Derby or Exeter). Initial assessments are conducted over three separate visits and then all participants will be scheduled to receive five consecutive days of a medication that has been identified as having the potential to reduce the impact of Long COVID. Following a period of 28 days, participants will be invited to repeat the same tests that were conducted before receiving the medication so that it can be determined how well the drug has worked. In this study we are specifically collecting information to understand how feasible this medication could be to help patients improve their condition and this will help us to determine how likely this drug is able to be used within the wider Long COVID community. The medication that will be used within this study is an existing anti-viral medication (Remdesivir). If we find patients are able to tolerate the treatment and the research tasks we will use this information to conduct a larger trial to determine how well this drug can be used to reduce the impact of Long COVID in a greater number of patients.
NCT05911906 ↗	An Open-label, Clinical Feasibility Study of the Efficacy of Remdesivir for Long-COVID.	Not yet recruiting	University Hospitals of Derby and Burton NHS Foundation Trust	Phase 4	2024-06-01	Following an infection with Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV2), one in ten people will experience persisting symptoms, or develop symptoms which can last for months and even years. These symptoms affect people in different ways and have been demonstrated to broadly impact physical, mental, and cognitive health. This is called Long COVID. Currently, there are no treatments available to address the issues that patients experience but anti-viral medications have been suggested as being potentially effective. This study will recruit patients that have confirmed long COVID and participants will undertake a series of tests to determine their symptoms and the impact that their condition has had on their bodily systems. The total duration of each participant's involvement is approximately 8 weeks, and this will involve 13 visits (15 visits if taking part in Exeter) at the closest study location (Derby or Exeter). Initial assessments are conducted over three separate visits and then all participants will be scheduled to receive five consecutive days of a medication that has been identified as having the potential to reduce the impact of Long COVID. Following a period of 28 days, participants will be invited to repeat the same tests that were conducted before receiving the medication so that it can be determined how well the drug has worked. In this study we are specifically collecting information to understand how feasible this medication could be to help patients improve their condition and this will help us to determine how likely this drug is able to be used within the wider Long COVID community. The medication that will be used within this study is an existing anti-viral medication (Remdesivir). If we find patients are able to tolerate the treatment and the research tasks we will use this information to conduct a larger trial to determine how well this drug can be used to reduce the impact of Long COVID in a greater number of patients.

Clinical Trial Conditions for Veklury

Condition Name

Condition Name for Veklury
Intervention	Trials
COVID-19	3
Covid19	2
COVID-19 Infection	1
Respiratory Syncytial Virus (RSV)	1

Condition MeSH

Condition MeSH for Veklury
Intervention	Trials
COVID-19	6
Post-Acute COVID-19 Syndrome	2
Communicable Diseases	1
Respiratory Syncytial Virus Infections	1

Clinical Trial Locations for Veklury

Trials by Country

Trials by Country for Veklury
Location	Trials
Spain	8
Brazil	7
Mexico	6
Argentina	4
Colombia	4

Clinical Trial Progress for Veklury

Clinical Trial Phase

Clinical Trial Phase for Veklury
Clinical Trial Phase	Trials
PHASE4	1
PHASE2	1
Phase 4	2

Clinical Trial Status

Clinical Trial Status for Veklury
Clinical Trial Phase	Trials
Completed	3
Recruiting	3
Not yet recruiting	2

Clinical Trial Sponsors for Veklury

Sponsor Name

Sponsor Name for Veklury
Sponsor	Trials
PharmaMar	1
Unity Health Toronto	1
ASST Fatebenefratelli Sacco	1

Sponsor Type

Sponsor Type for Veklury
Sponsor	Trials
Other	14
Industry	1
UNKNOWN	1

VEKLURY (remdesivir): Clinical Trials Update, Market Analysis, and Projection

Last updated: May 1, 2026

What is VEKLURY and what is its current clinical positioning?

VEKLURY is remdesivir (Gilead Sciences), an antiviral administered intravenously. Its core clinical positioning remains tied to hospitalized COVID-19 use, with label scope shaped by efficacy signals in pivotal trials and subsequent real-world and trial refinements.

Key clinical studies that established use

Trial / study	Population	Intervention	Primary context	Outcome signal (high level)
ACTT-1	Hospitalized COVID-19	Remdesivir vs placebo	Time to recovery	Improved time-to-recovery in earlier analyses (not uniform across all later subgroup analyses)
SIMPLE / pooled program	Hospitalized COVID-19	IV remdesivir regimens	Clinical status at predefined endpoint	Reduced time to recovery in some analyses; accelerated regulatory pathways
Real-world evidence	Mixed hospitalized settings	Remdesivir vs comparator	Mortality and clinical trajectory	Results vary by baseline severity, concomitant steroids, and evolving standard of care

What changed after authorization?

Post-2020, remdesivir’s clinical footprint shifted in line with:

• Standard-of-care evolution: corticosteroid adoption and other antivirals changed comparative dynamics.
• Disease-stage effects: benefit depends on baseline severity and timing from symptom onset.
• Emerging alternatives: oral antivirals and newer agents reduced reliance on IV remdesivir in some geographies and patient tiers.

Net effect: remdesivir remains an option for hospitalized patients where IV therapy is appropriate, but its incremental clinical value depends on current treatment pathways and eligibility criteria.

What clinical trials are actively shaping VEKLURY’s future?

VEKLURY’s near-term clinical relevance is increasingly driven by:

• New indication expansions (if any) and
• Comparative effectiveness in updated treatment algorithms.

At present, the practical clinical-trials landscape for remdesivir is more about survival within updated standards-of-care than about transformative new efficacy claims, with trial activity less visible than in the early pandemic phase.

What does the market look like today for VEKLURY?

Market structure

Remdesivir sales sit in a defined segment:

• Hospital acquisition channels
• Seasonal and outbreak-driven demand
• Formulary and guideline inclusion that shifts with:
  • variant waves
  • competing therapies
  • payer hospital contract terms

Competitive set

Remdesivir competes indirectly with:

• Oral antivirals for earlier outpatient intervention (reducing downstream hospital demand)
• Other hospitalized antivirals where available
• Supportive care plus immunomodulators in severe disease

Pricing and contracting reality

Hospital-IV antivirals generally face:

• tender-based pricing
• volume commitments
• restricted formulary placement
• policy-linked reimbursement

As COVID-19 testing and hospitalization patterns fluctuate, remdesivir’s market behaves like a policy and outbreak-sensitive hospital commodity, not a steadily expanding chronic-care product.

How large is the addressable demand pool (directionally)?

Demand for remdesivir is constrained by three structural limits:

1. Hospitalized COVID-19 incidence in each territory (wave-dependent)
2. Share of patients qualifying for IV antiviral use under local protocols
3. Treatment sequencing with corticosteroids and alternative antivirals

In practice, remdesivir’s peak demand occurred during earlier waves before:

• oral antivirals scaled,
• treatment algorithms stabilized,
• and competing products captured earlier lines of therapy.

What is the market projection for VEKLURY (base case, 3- to 5-year view)?

A realistic projection must reflect:

• continued episodic demand tied to COVID-19 hospitalization dynamics
• gradual but persistent substitution effects (oral antivirals and other agents)
• pricing pressure via contracting and procurement efficiencies

Projection framework

Driver	Directional impact	What it means for revenue
COVID hospitalization intensity	Volatile	Upside in outbreak peaks, downside in troughs
Guideline inclusion	Mostly stable but restrictive	Limits share capture; keeps remdesivir in formulary for hospitalized patients
Substitution by other therapies	Downward	Erodes incremental demand over time
Procurement and price	Downward	Mixed volume offsets lower net revenue per dose
Supply chain maturity	Neutral to positive	Reduces disruption risk, but does not create demand

Base case outcome (directional)

• Near-term: revenues track outbreak-driven utilization and tend to remain below peak-pandemic levels.
• Medium term (3-5 years): market compresses toward a maintenance level tied to severe hospitalized cases where IV antiviral therapy remains recommended or reimbursed.

What are the key business risks and upside levers?

Risks

• Guideline displacement: if hospitalized protocols further de-emphasize IV remdesivir.
• Patient selection tightening: narrower eligibility reduces eligible volume.
• Pricing resets: tender cycles can pressure net price.
• Indication drift: absence of new large-label expansions limits growth.

Upside levers

• Localized formulary persistence in high-need hospital systems.
• Treatment algorithm changes that re-legitimize IV antiviral use in specific severity/time windows.
• Stockpile and outbreak preparedness procurement in certain regions.

How does VEKLURY’s patent and lifecycle profile influence market outlook?

Remdesivir’s commercial planning depends heavily on:

• exclusivity windows (regulatory and patent)
• generic and biosimilar-like substitution timelines (for small-molecule, generic competition is the core risk)
• country-by-country patent status and enforcement

For IV antivirals, generic entry typically triggers:

• rapid share loss,
• net price collapse through tendering,
• and faster margin compression.

Given the age of the product and the small-molecule nature of remdesivir, the most material lifecycle risk is generic erosion, particularly in markets with lower enforcement or faster generic regulatory pathways.

Key Takeaways

• VEKLURY (remdesivir) remains anchored to hospitalized COVID-19, but its market is structurally shaped by outbreak-driven hospitalization demand and restrictive eligibility within updated treatment pathways.
• Clinical influence has stabilized since early pandemic evidence; ongoing relevance comes more from comparative positioning in modern algorithms than from new breakthrough efficacy claims.
• Market outlook is maintenance-to-decline relative to peak demand, with upside confined to outbreak peaks and formulary persistence while pricing and substitution drive the downside trend.
• Lifecycle risk is the dominant determinant of medium-term revenue trajectory, especially from generic competition and procurement-driven net price erosion.

FAQs

1. Is VEKLURY still used for COVID-19 in hospitals?
   Yes, in hospitalized COVID-19 settings where IV antiviral therapy fits local protocols and eligibility windows.

2. What limits remdesivir’s growth versus early-pandemic peaks?
   Evolving standards of care, narrower patient selection, and substitution by other antivirals and supportive regimens.

3. Does demand depend more on incidence or on treatment guidelines?
   Both matter, but incidence drives the upper bound while guidelines determine the fraction of hospitalized patients who actually receive IV remdesivir.

4. What is the largest business risk for VEKLURY?
   Generic substitution and tender-driven net price compression over the remaining lifecycle.

5. What would be the most credible upside scenario?
   Sustained or broadened hospital guideline inclusion for a defined severe subgroup with timing that preserves IV antiviral value.

---

References

[1] Gilead Sciences. VEKLURY (remdesivir) prescribing information.
[2] Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the treatment of COVID-19. N Engl J Med. 2020.
[3] Goldman JD, Lye DC, Döhler CK, et al. Remdesivir for 5 or 10 days in patients with severe COVID-19. N Engl J Med. 2020.
[4] ACTT-1 Investigators and collaborators. Adaptive COVID-19 Treatment Trial (ACTT-1) reports (peer-reviewed publications and trial registry updates).